These data suggest that our editing pipeline can be easily adapted to target patient-specific mutations in other regions of COL7A1 or used to edit other genes involved in a range of other EB subtypes and dermatological disorders. This evidence concerns the gene COL7A1 and epidermolysis bullosa.